VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
HUMHumana Inc.
$360.65$43.3B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
  1. Home
  2. Financial Ratios

  1. Home
  2. HUM
  3. Financial Ratios

Humana Inc. (HUM) Financial Ratios

30 years of historical data (1996–2025) · Healthcare · Medical - Healthcare Plans

View Quarterly Ratios →

P/E Ratio
↑
36.65
↑+55% vs avg
5yr avg: 23.60
096%ile100
30Y Low7.1·High50.1
View P/E History →
EV/EBITDA
↑
22.85
↑+40% vs avg
5yr avg: 16.31
0100%ile100
30Y Low0.5·High17.4
P/FCF
↑
115.47
↑+191% vs avg
5yr avg: 39.72
0100%ile100
30Y Low4.6·High82.5
P/B Ratio
↓
2.46
↓-18% vs avg
5yr avg: 3.01
060%ile100
30Y Low1.1·High4.2
ROE
↓
7.0%
↑-49% vs avg
5yr avg: 13.5%
017%ile100
30Y Low-26%·High26%
Debt/EBITDA
↑
5.68
↑+48% vs avg
5yr avg: 3.83
0100%ile100
30Y Low0.0·High5.7

Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.

HUM Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

Humana Inc. trades at 36.7x earnings, 55% above its 5-year average of 23.6x, sitting at the 96th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 66%. On a free-cash-flow basis, the stock trades at 115.5x P/FCF, 191% above the 5-year average of 39.7x.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$43.3B$30.9B$30.7B$57.0B$65.1B$60.0B$54.6B$49.4B$39.6B$36.1B$30.8B
Enterprise Value$52.0B$39.7B$40.7B$64.5B$71.8B$69.9B$57.0B$51.4B$43.4B$37.0B$31.0B
P/E Ratio →36.6526.0325.4222.8923.2020.4616.2118.2323.5614.7650.13
P/S Ratio0.330.240.260.540.700.720.710.760.700.670.57
P/B Ratio2.461.741.863.494.243.733.984.103.903.672.88
P/FCF115.4782.5312.8319.1418.8765.2411.6710.8625.4010.2521.85
P/OCF47.0133.6010.3414.3114.1926.539.689.3518.258.9215.90

P/E links to full P/E history page with 30-year chart

HUM EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

Humana Inc.'s enterprise value stands at 22.9x EBITDA, 40% above its 5-year average of 16.3x. The Healthcare sector median is 14.2x, placing the stock at a 61% premium on an enterprise-value basis.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—0.310.350.610.770.840.740.790.760.690.57
EV / EBITDA22.8517.4315.6915.2316.2816.9110.7812.7216.639.7114.06
EV / EBIT35.8119.0417.8016.9318.1118.6511.5113.8618.927.7914.06
EV / FCF—105.8217.0221.6820.8175.9312.2011.3127.7910.4922.01

HUM Profitability

Margins and return-on-capital ratios measuring operating efficiency

Humana Inc. earns an operating margin of 1.1%. Operating margins have compressed from 3.1% to 1.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 7.0% is modest. ROIC of 4.1% represents below-average returns on invested capital.

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin14.5%14.5%14.6%17.0%18.5%17.3%20.3%17.2%19.7%13.2%14.3%
Operating Margin1.1%1.1%1.4%3.1%3.8%4.1%6.1%5.3%3.6%6.2%3.2%
Net Profit Margin0.9%0.9%1.0%2.3%3.0%3.5%4.4%4.2%3.0%4.6%1.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE7.0%7.0%7.4%15.7%17.8%19.7%26.1%24.4%16.8%23.9%5.8%
ROA2.5%2.5%2.6%5.5%6.3%7.3%10.5%10.0%6.5%9.3%2.4%
ROIC4.1%4.1%4.8%10.8%11.1%12.2%23.1%18.6%12.6%23.1%11.5%
ROCE4.0%4.0%4.6%9.9%10.7%11.3%19.3%16.9%10.1%15.6%8.7%

HUM Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

Humana Inc. carries a Debt/EBITDA ratio of 5.7x, which is highly leveraged (77% above the sector average of 3.2x). Net debt stands at $8.7B ($12.9B total debt minus $4.2B cash). Interest coverage of 3.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.730.730.750.750.760.820.520.510.600.500.38
Debt / EBITDA5.685.684.722.902.673.201.351.512.331.291.85
Net Debt / Equity—0.490.610.460.440.610.180.170.370.090.02
Net Debt / EBITDA3.843.843.871.791.522.380.470.511.430.230.10
Debt / FCF—23.304.202.541.9410.690.530.452.390.250.15
Interest Coverage3.303.303.477.739.8911.4917.5215.3410.5119.6211.67

HUM Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

The current ratio of 0.72x is below 1.0, meaning current liabilities exceed current assets — though the company's $4.2B cash position helps mitigate short-term liquidity concerns. The current ratio has improved from 0.56x to 0.72x over the past 3 years.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio0.720.720.440.560.580.500.650.750.511.120.86
Quick Ratio0.720.720.440.560.580.500.650.750.511.120.86
Cash Ratio0.410.410.200.390.440.320.520.600.360.920.71
Asset Turnover—2.662.542.272.131.872.202.242.252.022.11
Inventory Turnover———————————
Days Sales Outstanding———————————

HUM Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Humana Inc. returns 1.3% to shareholders annually — split between a 1.0% dividend yield and 0.3% buyback yield. The payout ratio of 36.2% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 2.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield1.0%1.4%1.4%0.8%0.6%0.6%0.6%0.6%0.7%0.6%0.6%
Payout Ratio36.2%36.2%35.7%17.3%14.0%12.1%9.6%10.7%15.7%9.0%28.8%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield2.7%3.8%3.9%4.4%4.3%4.9%6.2%5.5%4.2%6.8%2.0%
FCF Yield0.9%1.2%7.8%5.2%5.3%1.5%8.6%9.2%3.9%9.8%4.6%
Buyback Yield0.3%0.5%2.7%2.8%3.2%0.1%3.3%2.2%2.7%9.3%0.3%
Total Shareholder Yield1.3%1.9%4.1%3.5%3.8%0.7%3.9%2.8%3.4%9.9%0.9%
Shares Outstanding—$121M$121M$124M$127M$129M$133M$135M$138M$146M$151M

Peer Comparison

Compare HUM with 10 similar companies in its peer group

CompanyMarket CapP/EEV/EBITDAP/FCFGross MarginOp MarginROEROICDebt/EBITDA
HUM logoHUMYou$43B36.722.9115.514.5%1.1%7.0%4.1%5.7
UNH logoUNH$364B30.317.922.618.5%4.2%11.8%9.2%3.4
CVS logoCVS$125B70.714.016.113.8%2.6%2.3%5.0%6.2
ELV logoELV$84B15.511.226.625.6%4.1%13.3%9.1%3.4
CNC logoCNC$30B-4.5—7.012.2%-3.9%-28.7%-21.6%—
MOH logoMOH$10B21.910.1—9.0%1.7%11.0%17.4%4.0
ALHC logoALHC$4B-5908.193.439.512.4%0.4%-0.5%—7.5
OSCR logoOSCR$7B-16.8—7.014.4%-3.4%-44.4%——
CLOV logoCLOV$3B-29.4——18.5%-4.4%-26.3%-34.0%—
BHVN logoBHVN$1B-2.0————-310.8%-242.1%—
ACGL logoACGL$32B7.86.65.337.2%25.0%19.5%15.4%0.5
Healthcare Median—22.114.218.563.9%-4.3%-32.6%-11.6%3.2

Peer selection based on competitive and market overlap. Compare multiple stocks →

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into HUM consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HUM — Frequently Asked Questions

Quick answers to the most common questions about buying HUM stock.

What is Humana Inc.'s P/E ratio?

Humana Inc.'s current P/E ratio is 36.7x. The historical average is 19.2x. This places it at the 96th percentile of its historical range.

What is Humana Inc.'s EV/EBITDA?

Humana Inc.'s current EV/EBITDA is 22.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.6x.

What is Humana Inc.'s ROE?

Humana Inc.'s return on equity (ROE) is 7.0%. The historical average is 13.0%.

Is HUM stock overvalued?

Based on historical data, Humana Inc. is trading at a P/E of 36.7x. This is at the 96th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Humana Inc.'s dividend yield?

Humana Inc.'s current dividend yield is 0.99% with a payout ratio of 36.2%.

What are Humana Inc.'s profit margins?

Humana Inc. has 14.5% gross margin and 1.1% operating margin.

How much debt does Humana Inc. have?

Humana Inc.'s Debt/EBITDA ratio is 5.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.